Related Experiment Video

Updated: Jul 13, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Detection of familial hypercholesterolaemia: a major treatment gap in preventative cardiology

Timothy R Bates1, John R Burnett, Frank M van Bockxmeer

  • 1Lipid Disorders Clinic and Department of Internal Medicine, Royal Perth Hospital, GPO Box X2213, Perth, Western Australia 6847, Australia.

Heart, Lung & Circulation
|August 9, 2007
PubMed

Insights

Familial hypercholesterolaemia (FH), a genetic disorder increasing coronary artery disease (CAD) risk, is underdiagnosed and undertreated. Many patients with premature CAD lack FH diagnosis and appropriate statin therapy, highlighting a critical gap in cardiovascular prevention.

Area of Science:

  • Cardiology
  • Genetics
  • Public Health

Background:

  • Familial hypercholesterolaemia (FH) is a prevalent genetic disorder.
  • Untreated FH confers a nearly 100-fold increased risk of coronary artery disease (CAD).
  • Early detection and treatment are crucial for preventing cardiovascular events.

Purpose of the Study:

  • To audit the identification and management of FH in patients with premature CAD.
  • To assess the gap in coronary prevention strategies related to FH.

Main Methods:

  • Retrospective audit of 334 patients with premature CAD admitted to a cardiology department.
  • Evaluation of medical records for sufficient clinical information to identify FH.
  • Application of recognized clinical criteria to diagnose possible to definite FH.
  • Analysis of statin therapy use and adherence to treatment targets.

Main Results:

  • Only 60% of medical records contained adequate information for FH identification.
  • Among records with sufficient data, 54% indicated possible to definite FH.
  • Only 38% of identified FH patients were on statin therapy.
  • A mere 22% of FH patients met National Heart Foundation treatment targets.

Conclusions:

  • There is a significant deficit in the detection of FH among patients with premature CAD.
  • Inadequate treatment, particularly statin therapy, is prevalent in diagnosed FH patients.
  • Addressing these gaps is essential for improving coronary prevention strategies.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...